Ticagrelor versus clopidogrel in STEMI post-PCI: A mixed-design meta-analysis of efficacy and safety

Q: What are the key findings of this study?

Ticagrelor significantly reduced all-cause mortality by 36% (OR 0.64) compared to clopidogrel in STEMI patients post-PCI.

Q: What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: STEMI post-PCI (n=31729). Intervention: Ticagrelor vs. Clopidogrel. Primary outcome: All-cause mortality (OR 0.64, 95% CI 0.47-0.88, p=0.006).

Q: What does this research mean for the field?

In STEMI patients post-PCI, ticagrelor outperforms clopidogrel by significantly reducing mortality, major adverse cardiovascular events, myocardial infarction, stent thrombosis, and major bleeding, although it increases the risk of target vessel revascularization. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Mohammad Maroof Shahid; Muhammad Hamza Sajjad; Sanket Kumar Pankajbhai Patel; Moosa Feroze Tarar; Malik Abdullah Rasheed; Muhammad Soban Jaffar; Muhammad Ali Rana; Mohammad Hamza Abbas; Abdul Basit Rasheed; Maira Shahid; Mirza Muhammad Hadeed Khawar; Elham Shenawa

doi:10.1097/md.0000000000049923

July 24, 2026MedicineOpen Access

Ticagrelor versus clopidogrel in STEMI post-PCI: A mixed-design meta-analysis of efficacy and safety

View Full Paper

Ask AI

Bookmark

Share

Key result

Ticagrelor cuts all-cause mortality ~36% vs. clopidogrel in STEMI patients post-PCI.

OR 0.64
95% CI 0.47-0.88
P=0.006
n=31,729

Figures

Why the study?

Ticagrelor provides faster and stronger platelet inhibition than clopidogrel, but evidence regarding its efficacy and safety in STEMI patients post-PCI is conflicting.

Does ticagrelor reduce adverse cardiovascular outcomes and mortality compared to clopidogrel in adult STEMI patients post-PCI?

Key Points

To compare the efficacy and safety of ticagrelor versus clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Conducted a systematic review and meta-analysis adhering to PRISMA 2020 guidelines across PubMed, Embase, ScienceDirect, and ClinicalTrials.gov through July 2025.
Included 8 studies (5 randomized controlled trials and 3 observational studies) comprising 31,729 adult STEMI patients post-PCI (16,560 receiving ticagrelor and 15,169 receiving clopidogrel).
Calculated pooled odds ratios (ORs) with 95% confidence intervals (CIs) using random-effects models.
Ticagrelor significantly reduced all-cause mortality (OR = 0.64, 95% CI = 0.47–0.88; P = .006), cardiovascular mortality (OR = 0.68, 95% CI = 0.60–0.93; P = .01), and major adverse cardiovascular events (OR = 0.71, 95% CI = 0.60–0.84; P = .01).
Ticagrelor significantly lowered the risk of myocardial infarction (OR = 0.71, 95% CI = 0.61–0.83; P < .00001), stent thrombosis (OR = 0.66, 95% CI = 0.55–0.79; P < .00001), and major bleeding (OR = 0.87, 95% CI = 0.78–0.97; P = .01).
Target vessel revascularization was significantly higher with ticagrelor (OR = 1.30, 95% CI = 1.05–1.61; P = .02), while stroke risk showed no significant difference between treatments (OR = 1.16, 95% CI = 0.89–1.52; P = .28).

Study Design

Type

Meta-Analysis (n=31,729)

Structured PICO

Does ticagrelor reduce adverse cardiovascular outcomes and mortality compared to clopidogrel in adult STEMI patients post-PCI?

P

Population

31,729 adult STEMI patients undergoing primary PCI, pooled from 8 studies (5 RCTs, 3 observational) comparing ticagrelor to clopidogrel.

I

Intervention

Ticagrelor as part of dual antiplatelet therapy (with or without concomitant aspirin)

C

Comparator

Clopidogrel as part of dual antiplatelet therapy (with or without concomitant aspirin)

O

Outcome

Myocardial infarction, stent thrombosis, stroke, target vessel revascularization (TVR), all-cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), or major bleeding at longest available follow-up (minimum 30 days, prioritizing 1-year data)hard clinical

Main Result

Odds Ratio: 0.64 (95% CI 0.47–0.88)

p-value: p=0.006

In STEMI patients undergoing primary PCI, ticagrelor significantly reduces mortality, MACE, and stent thrombosis compared to clopidogrel, though it is associated with an increased risk of target vessel revascularization.

Limitations

Inclusion of both RCTs and observational studies introduces inherent heterogeneity and potential confounding
Varying follow-up periods across studies, ranging from 30 days to 12 months
Limited by availability of aggregate-level data rather than individual patient data
Potential publication bias for smaller studies with negative results
Heavy reliance on PLATO trial data which has documented controversies
Pooling of studies with heterogeneous bleeding criteria
Inclusion of observational studies with moderate risk of bias
Substantial heterogeneity in several key outcomes such as all-cause mortality, cardiovascular mortality, and MACE
Limited number of studies per outcome

Implication

Supports ticagrelor over clopidogrel for mortality reduction in STEMI post-PCI; extends RCT evidence with observational data.

Abstract

Background: ST-segment elevation myocardial infarction (STEMI) requires primary percutaneous coronary intervention (PCI) and dual antiplatelet therapy with aspirin and a purinergic receptor Y12 inhibitor to reduce thrombotic risks. Ticagrelor, a potent purinergic receptor Y12 inhibitor, offers faster and stronger platelet inhibition than clopidogrel, but evidence on its efficacy and safety in STEMI patients post-PCI is conflicting. This study aims to compare the efficacy and safety of ticagrelor versus clopidogrel in STEMI patients undergoing primary PCI. Methods: This systematic review and meta-analysis, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, searched PubMed, Embase, ScienceDirect, and ClinicalTrials.gov up to July 2025. Included were randomized controlled trials and observational studies comparing ticagrelor to clopidogrel in adult STEMI patients post-PCI, reporting cardiovascular outcomes. Data were pooled using odds ratios (ORs) with 95% confidence intervals (CIs) via random-effects models. Results: Eight studies (5 randomized controlled trials, 3 observational; n = 31,729) showed ticagrelor significantly reduced all-cause mortality (OR = 0.64, 95% CI = 0.47–0.88; P = .006), cardiovascular mortality (OR = 0.68, 95% CI = 0.60–0.93; P = .01), major adverse cardiovascular events (OR = 0.71, 95% CI = 0.60–0.84; P = .01), myocardial infarction (OR = 0.71, 95% CI = 0.61–0.83; P < .00001), stent thrombosis (OR = 0.66, 95% CI = 0.55–0.79; P < .00001), and major bleeding (OR = 0.87, 95% CI = 0.78–0.97; P = .01), but increased target vessel revascularization (OR = 1.30, 95% CI = 1.05–1.61; P = .02). No significant difference was observed in stroke risk (OR = 1.16, 95% CI = 0.89–1.52; P = .28). Conclusion: Ticagrelor outperforms clopidogrel in STEMI post-PCI, reducing key adverse outcomes, though higher target vessel revascularization risk warrants caution.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shahid et al. (2026) conducted a meta-analysis in STEMI post-PCI (n=31,729). Ticagrelor vs. Clopidogrel was evaluated on All-cause mortality (OR 0.64, 95% CI 0.47-0.88, p=0.006). Ticagrelor significantly reduced all-cause mortality by 36% (OR 0.64) compared to clopidogrel in STEMI patients post-PCI.

synapsesocial.com/papers/6a65282f310af27a437e9340 https://doi.org/10.1097/md.0000000000049923

View Full Paper

Ask AI

Bookmark

Share

Ticagrelor versus clopidogrel in STEMI post-PCI: A mixed-design meta-analysis of efficacy and safety

Figures

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Ticagrelor versus clopidogrel in STEMI post-PCI: A mixed-design meta-analysis of efficacy and safety

Figures

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading